Inflammatory Bowel Disease
VIDEO: Rebyota effective in prevention of recurrent C. diff, even in higher risk patients
PHILADELPHIA — Rebyota was safe and effective at 8 weeks and up to 6 months in patients with recurrent Clostridioides difficile infection, many of whom had other gastrointestinal comorbidities and risk factors, according to data presented.
No increased risk for IBD flare 1 year after gender-affirming hormone therapy
PHILADELPHIA — Although there was no overall increased risk for flare 1 year after gender-affirming hormone therapy in patients with inflammatory bowel disease, active IBD and receiving testosterone increased the likelihood of a flare.
‘No clear efficacy benefit’ to combining bezlotoxumab with FMT in IBD, recurrent C. diff
PHILADELPHIA — Bezlotoxumab in combination with fecal microbiota transplantation did not further reduce recurrence of Clostridioides difficile infection in patients with inflammatory bowel disease, according to data presented here.
VIDEO: ‘No significant difference’ in cardiovascular events with JAKs vs. anti-TNF for IBD
PHILADELPHIA — Use of Janus kinase inhibitors did not increase the risk for major cardiovascular or thromboembolic events among patients with inflammatory bowel disease compared with anti-tumor necrosis factor therapy, data showed.
VIDEO: Primary sclerosing cholangitis increases risk for CRC, even among those without IBD
PHILADELPHIA — Primary sclerosing cholangitis is an independent risk factor for colorectal cancer, with an “almost three-times higher” risk among patients without inflammatory bowel disease vs. the general population, a researcher reported.
FDA expands approval of Stelara biosimilar Selarsdi to include UC, Crohn’s disease
The FDA approved the Stelara biosimilar, Selarsdi, as a 130 mg/26 mL single-dose IV infusion for adult patients with Crohn’s disease and ulcerative colitis, Alvotech and Teva Pharmaceuticals announced in a press release.
Mirikizumab bests ustekinumab in histologic response at week 52 in Crohn’s
More patients with moderate to severe Crohn’s disease achieved histologic response at week 52 with mirikizumab vs. ustekinumab, regardless of prior biologic exposure, according to data presented at UEG Week.
Rinvoq outperforms placebo in drainage resolution, closure in perianal fistulizing Crohn’s
Treatment with Rinvoq resulted in higher rates of closure of external openings and drainage resolution vs. placebo in perianal fistulizing Crohn’s disease, according to pooled data from the U-EXCEL, U-EXCEED and U-ENDURE trials.
JAK inhibitors: ‘A valuable addition’ to the IBD treatment portfolio
This month’s Healio Exclusive highlights the efficacy of Janus kinase inhibitors in the management of ulcerative colitis and Crohn’s disease.
‘Don’t shy away’ from JAKs in IBD: Monitor patient outcomes, understand potential risks
Despite an existing class-wide black box warning, 45% of health care providers felt cardiovascular concerns related to Janus kinase inhibitors “were irrelevant” to patients with inflammatory bowel disease, according to survey results.